CY1111921T1 - 7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ - Google Patents

7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ

Info

Publication number
CY1111921T1
CY1111921T1 CY20111100618T CY111100618T CY1111921T1 CY 1111921 T1 CY1111921 T1 CY 1111921T1 CY 20111100618 T CY20111100618 T CY 20111100618T CY 111100618 T CY111100618 T CY 111100618T CY 1111921 T1 CY1111921 T1 CY 1111921T1
Authority
CY
Cyprus
Prior art keywords
benzisoxazol
triazolo
pyrazolo
pyrimidin
propynyl
Prior art date
Application number
CY20111100618T
Other languages
English (en)
Inventor
Craig D Boyle
Samuel Chackalamannil
Unmesh G Shah
Jean E Lachowicz
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37487759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111921(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1111921T1 publication Critical patent/CY1111921T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Αποκαλύπτεται η ένωση που έχει τον συντακτικό τύπο I, ή φαρμακευτικώς αποδεκτό άλας της, καθώς και η χρήση της στη θεραπεία νόσων του κεντρικού νευρικού συστήματος, συγκεκριμένα της νόσου του Parkinson, εξωπυραμιδικού συνδρόμου, συνδρόμου ανώμαλης κίνησης σκελών και διαταραχής υπεραντιδραστικότητας ελλείμματος προσοχής, φαρμακευτικές συνθέσεις που την περιέχουν, και συνδυασμοί με άλλα μέσα.
CY20111100618T 2005-09-23 2011-06-28 7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ CY1111921T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72002705P 2005-09-23 2005-09-23
EP06804036A EP1937687B1 (en) 2005-09-23 2006-09-21 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE

Publications (1)

Publication Number Publication Date
CY1111921T1 true CY1111921T1 (el) 2015-11-04

Family

ID=37487759

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100618T CY1111921T1 (el) 2005-09-23 2011-06-28 7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ

Country Status (31)

Country Link
US (2) US7572802B2 (el)
EP (1) EP1937687B1 (el)
JP (1) JP4808779B2 (el)
KR (1) KR101396614B1 (el)
CN (2) CN102716131B (el)
AR (1) AR056080A1 (el)
AT (1) ATE503759T1 (el)
AU (1) AU2006294633B8 (el)
BR (1) BRPI0616264B8 (el)
CA (1) CA2623047C (el)
CY (1) CY1111921T1 (el)
DE (1) DE602006021042D1 (el)
DK (1) DK1937687T3 (el)
EC (1) ECSP088297A (el)
ES (1) ES2361856T3 (el)
HK (1) HK1119681A1 (el)
HR (1) HRP20110466T1 (el)
IL (1) IL190275A (el)
MY (1) MY146429A (el)
NO (1) NO341760B1 (el)
NZ (1) NZ566737A (el)
PE (1) PE20070521A1 (el)
PL (1) PL1937687T3 (el)
PT (1) PT1937687E (el)
RS (1) RS51702B (el)
RU (1) RU2417997C2 (el)
SG (1) SG165419A1 (el)
SI (1) SI1937687T1 (el)
TW (1) TWI335329B (el)
WO (1) WO2007038284A1 (el)
ZA (1) ZA200802550B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US8598343B2 (en) 2009-08-07 2013-12-03 Merck Sharp & Dohme Corp. Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
CA2812378C (en) * 2010-09-24 2016-11-29 Advinus Therapeutics Limited Fused tricyclic compounds as adenosine receptor antagonist
WO2012135083A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 7-(2-(4-(6-FLUORO-3-METHYLBENZO[d]ISOXAZOL-5-YL)PIPERAZIN-1-YL)ETHYL)-2-(PROP-1-YNYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014128882A1 (ja) * 2013-02-21 2014-08-28 医療法人 和楽会 不安うつ病の治療薬
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
CN111943890B (zh) 2014-11-03 2023-10-31 艾欧米制药有限公司 药用化合物
WO2016089796A1 (en) * 2014-12-04 2016-06-09 Merck Sharp & Dohme Corp. Formulation inhibiting effects of low acid environment
CN106543095B (zh) * 2016-09-23 2019-03-05 江苏大学 一种基于2-羟基苯乙酮肟及其衍生物一锅制备苯并异噁唑的方法
WO2019118313A1 (en) 2017-12-13 2019-06-20 Merck Sharp & Dohme Corp. Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE462170B (sv) 1987-10-27 1990-05-14 Aahlstrom Corp Avlaegsnande av loesta och kolloidala makromolekylaera organiska aemnen ur effluenter
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) * 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1275420B (it) 1995-06-02 1997-08-05 Schering Plough S P A Metodo per misurare l'affinita' di legame al recettore a2a dell'adenosina di componenti di interesse farmacologico mediante l'uso del ligando triziato (3h)-sch 58261
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
KR100520907B1 (ko) 2000-05-26 2005-10-11 쉐링 코포레이션 아데노신 Ａ2ａ수용체 길항제
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
KR100687954B1 (ko) 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
US7414058B2 (en) 2002-12-19 2008-08-19 Schering Corporation Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
BRPI0409787B8 (pt) * 2003-04-23 2021-05-25 Merck Sharp & Dohme antagonistas receptores da 2-alquinil- e 2-alquenil-pirazol-[4,3-e]-1,2,4-triazol-[1,5-c]-pirimidina adenosina a2a
ES2342082T3 (es) 2004-04-21 2010-07-01 Schering Corporation Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina.

Also Published As

Publication number Publication date
AU2006294633A1 (en) 2007-04-05
AU2006294633B8 (en) 2012-03-29
NZ566737A (en) 2011-09-30
TWI335329B (en) 2011-01-01
HK1119681A1 (en) 2009-03-13
CN102716131B (zh) 2014-04-23
BRPI0616264B8 (pt) 2021-05-25
KR20080047423A (ko) 2008-05-28
WO2007038284A1 (en) 2007-04-05
PT1937687E (pt) 2011-06-01
BRPI0616264B1 (pt) 2020-12-22
CA2623047C (en) 2013-04-23
MY146429A (en) 2012-08-15
IL190275A0 (en) 2009-09-22
US8389532B2 (en) 2013-03-05
CN101273045A (zh) 2008-09-24
ATE503759T1 (de) 2011-04-15
ES2361856T3 (es) 2011-06-22
CA2623047A1 (en) 2007-04-05
PL1937687T3 (pl) 2011-09-30
SG165419A1 (en) 2010-10-28
CN102716131A (zh) 2012-10-10
AU2006294633A8 (en) 2012-03-29
JP4808779B2 (ja) 2011-11-02
RU2417997C2 (ru) 2011-05-10
BRPI0616264A2 (pt) 2011-06-14
ECSP088297A (es) 2008-04-28
NO341760B1 (no) 2018-01-15
US20070072867A1 (en) 2007-03-29
AU2006294633B2 (en) 2012-03-01
US20090270432A1 (en) 2009-10-29
HRP20110466T1 (hr) 2011-08-31
DK1937687T3 (da) 2011-07-18
KR101396614B1 (ko) 2014-05-16
DE602006021042D1 (de) 2011-05-12
NO20081924L (no) 2008-05-22
SI1937687T1 (sl) 2011-07-29
PE20070521A1 (es) 2007-07-13
EP1937687B1 (en) 2011-03-30
AR056080A1 (es) 2007-09-19
IL190275A (en) 2014-06-30
TW200730531A (en) 2007-08-16
RU2008115239A (ru) 2009-10-27
RS51702B (en) 2011-10-31
ZA200802550B (en) 2009-06-24
EP1937687A1 (en) 2008-07-02
CN101273045B (zh) 2012-02-01
JP2009509959A (ja) 2009-03-12
US7572802B2 (en) 2009-08-11

Similar Documents

Publication Publication Date Title
CY1111921T1 (el) 7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ
SE0402735D0 (sv) Novel compounds
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ECSP066718A (es) Derivados de pirazolo[1,5-a]pirimidin-7-il-amina para usar en el tratamiento de enfermedades dependientes de la proteina quinasa
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
ECSP066948A (es) Benzoxazinas para el tratamiento de enfermedades de las vías respiratorias
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
TW200700392A (en) Novel compounds
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
PE20080548A1 (es) Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de cinasa de proteina
PT1771178E (pt) Utilização de k-252a e de inibidores de quinase para a prevenção ou o tratamento de patologias associadas a hmgb1
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
CY1109263T1 (el) Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
HRP20120918T1 (hr) Aminopirazolski spoj
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
EA200800223A1 (ru) ПРОИЗВОДНЫЕ ПИРИДО[2,3-d]ПИРИМИДИНА, ИХ ПОЛУЧЕНИЕ, ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
BRPI0410986A (pt) derivados de estaurosporina para sìndrome hipereosinofìlica
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
TW200700067A (en) Substituted aryl 1,4-pyrazine derivatives
EA200602154A1 (ru) Пиридин-4-илэтинилимидазолы и -пиразолы как антагонисты рецептора mglu5
BRPI0507811A (pt) derivados de 7h-pirrolopirimidina